| 395.93 6.16 (1.58%) | 04-26 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 491.72 | 1-year : | 574.33 |
| Resists | First : | 421 | Second : | 491.72 |
| Pivot price | 391.74 |
|||
| Supports | First : | 380.7 | Second : | 355.79 |
| MAs | MA(5) : | 393.33  |
MA(20) : | 392.63 |
| MA(100) : | 349.35 |
MA(250) : | 286.48 |
|
| MACD | MACD : | -0.6 |
Signal : | -0.6 |
| %K %D | K(14,3) : | 59.2 |
D(3) : | 61.1 |
| RSI | RSI(14): 52.2 |
|||
| 52-week | High : | 421 | Low : | 197.38 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ MEDP ] has closed below upper band by 40.9%. Bollinger Bands are 5.6% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 397.37 - 399.33 | 399.33 - 401.31 |
| Low: | 384.26 - 386.3 | 386.3 - 388.36 |
| Close: | 392.64 - 395.88 | 395.88 - 399.16 |
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. It offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. The company also provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, it offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The company was founded in 1992 and is based in Cincinnati, Ohio.
Fri, 26 Apr 2024
Medpace Holdings, Inc. to Post Q2 2024 Earnings of $2.43 Per Share, William Blair Forecasts (NASDAQ:MEDP) - MarketBeat
Fri, 26 Apr 2024
MEDP (Medpace Holdings) Peter Lynch Fair Value - GuruFocus.com
Thu, 25 Apr 2024
Medpace Holdings First Quarter 2024 Earnings: EPS Beats Expectations - Simply Wall St
Wed, 24 Apr 2024
Medpace Holdings, Inc. (NASDAQ:MEDP) Q1 2024 Earnings Call Transcript - Yahoo Finance Australia
Wed, 24 Apr 2024
Medpace Holdings Inc (MEDP) Q1 2024 Earnings Call Transcript Highlights: Robust Growth and Optimistic Projections - GuruFocus.com
Tue, 23 Apr 2024
Medpace Holdings, Inc. (MEDP) Q1 2024 Earnings Call Transcript - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Outperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 31 (M) |
| Shares Float | 25 (M) |
| Held by Insiders | 18.1 (%) |
| Held by Institutions | 82.6 (%) |
| Shares Short | 947 (K) |
| Shares Short P.Month | 937 (K) |
| EPS | 8.89 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 18.21 |
| Profit Margin | 15 % |
| Operating Margin | 17.5 % |
| Return on Assets (ttm) | 13.9 % |
| Return on Equity (ttm) | 59.8 % |
| Qtrly Rev. Growth | 26.5 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 61 |
| EBITDA (p.s.) | 11.72 |
| Qtrly Earnings Growth | 16.5 % |
| Operating Cash Flow | 433 (M) |
| Levered Free Cash Flow | 346 (M) |
| PE Ratio | 44.48 |
| PEG Ratio | 1.9 |
| Price to Book value | 21.73 |
| Price to Sales | 6.48 |
| Price to Cash Flow | 28.3 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|